English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDana-Farber Cancer Institute (Boston, MA, USA) and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the third Transatlantic Exchange in Oncology Conference will address: Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.The meeting, supported by L’Institut Servier, will be held in-person (witha virtual attendance option) on April 12, 2024, at the Revere Hotel Boston Common and livestreamed virtually on Medscape’s platform.
Tag: Dana Farber Cancer Institute
Dana-Farber Cancer Institute receives $10 million gift from the Linde Family Foundation
The Linde Family Foundation has made a $10 million gift to launch the Center for Therapeutic Discovery at Dana-Farber Cancer Institute. This new center will be home to a new team devoted to the development of novel therapeutics for patients with rare and hard-to-treat cancers.
Season two of Unraveled: A Dana-Farber podcast is now available
The second season of Unraveled: A Dana-Farber Cancer Institute podcast is now available with six new episodes telling stories of the science and scientists behind some of the most important cancer discoveries, diving deep into the lab.
Dana-Farber researcher awarded Victoria Mock New Investigator Award
Rachel Pozzar, PhD, RN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, has been awarded the 2023 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award.
Dana-Farber Brigham Cancer Center is ranked the best in New England
Dana-Farber Brigham Cancer Center is ranked #4 as a Best Hospital for cancer care by U.S. News and World Report for 2021-22
Immunotherapy – targeted drug combination improves survival in advanced kidney cancer
Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Dana-Farber to hold a discussion for cancer patients and survivors about the Covid-19 vaccine
Dana-Farber Cancer Institute is having a virtual discussion for cancer patients and survivors about the Covid-19 vaccine on January 27, 2020 at 5 pm.
John Ryan named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has appointed John Ryan to be its next Senior Vice President, General Counsel and Chief Governance Officer, effective December 14. Ryan has extensive expertise representing health care and life sciences organizations in public company and non-profit settings. He has managed a wide range of legal matters, including medical research and technology, clinical care, IP protection and international expansion.
Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma
Dana-Farber Cancer Institute, one of the world’s leading centers of cancer research and treatment, and Quest Diagnostics, (NYSE: DGX), the world’s leading provider of diagnostic information services, announced the start of a new research study that provides free COVID-19 antibody testing to individuals who are at high risk of developing multiple myeloma.
Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval
Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy.
Dana-Farber to test blood cancer drug in COVID-19 patients
Scientists at Dana-Farber Cancer Institute have launched a clinical test of a blood cancer drug in patients infected with the COVID-19 virus.
SHE Center at Dana-Farber and Silverberry Genomix form SHE Biobank, a Population Health Initiative for Research and Education
Dana-Farber and Silverberry Genomix launch the SHE Biobank initiative — a long-term study to investigate the impact of genetic predisposition and environmental exposure to development of disease.
Dana-Farber Cancer Institute to Establish Riney Family Multiple Myeloma Initiative
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.
Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.
New blood test capable of detecting multiple types of cancer
A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.